Summary by Moomoo AI
Wuxi Bio's revenue increased slightly by 1.0% in the six months ending June 30, 2024, reaching RMB 857.42 million, while gross profit decreased by 5.9% year-on-year to RMB 335.00 million. Net profit attributable to shareholders and net profit attributable to the company both decreased by 23.9% and 33.9% respectively to RMB 178.03 million and RMB 149.91 million. Adjusted net profit and adjusted net profit attributable to the company both decreased by 13.0% and 20.7% respectively to RMB 254.48 million and RMB 225.03 million. During the reporting period, the Group repurchased and cancelled shares, and entered into a share transfer agreement with Shanghai Hile Bio-technology after June 30, 2024, conditionally agreeing to purchase a 30% equity interest in WuXi Hyd.
